Key Takeaway: Precision BioSciences has reported positive results from its fourth quarter and fiscal year 2025, highlighting the successful execution of the Phase 1 ELIMINATE-B trial for PBGENE-HBV. The trial has dosed 13 patients across the first five cohorts, demonstrating safety, tolerability, and promising antiviral activity. These findings were showcased in a Late Breaker presentation at AASLD, The Liver Meeting.
Price reaction · baseline $5.06 (2026-03-11 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+12.1%
day 1
+12.1%
day 3 · peak
+37%
Market Sentiment Analysis
POSITIVE FACTORS
Successful Phase 1 trial execution for PBGENE-HBV.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity – – Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates
Frequently Asked Questions
What were the results of the PBGENE-HBV Phase 1 trial?
The PBGENE-HBV Phase 1 trial showed safety, tolerability, and dose-dependent antiviral activity.
How many patients were dosed in the ELIMINATE-B trial?
Thirteen patients have been dosed across the first five cohorts of the ELIMINATE-B trial.
Where was the PBGENE-HBV data presented?
The data was presented at AASLD, The Liver Meeting, in a Late Breaker session.
What is the focus of Precision BioSciences' recent update?
The update focuses on the financial results and progress of the PBGENE-HBV trial.